Professor of Medicine, Cedars-Sinai Medical Center; Professor of Medicine, University of California, Los Angeles; Co-Director, Experimental Therapeutics Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Hospital.
Monica Mita, MD, MDSc, is the co-director of the Experimental Therapeutics Program at the Samuel Oschin Comprehensive Cancer Institute (SOCCI) at Cedars Sinai Hospital, Los Angeles, and professor of medicine at Cedars Sinai and the University of California, Los Angeles. Dr. Mita obtained her MD from the University of Medicine Carol Davilla in Bucharest. She then moved to France, where she obtained a Master’s of Science degree from the University Paris-Sud, and performed her residency and fellowship in oncology in Paris and Toulouse. Upon moving back to the US, Dr. Mita performed a second fellowship in medical oncology and a fellowship in drug development in San Antonio, TX. She remained in San Antonio for almost 10 years, initially as a fellow at UT Health San Antonio, then as staff physician and assistant professor of medicine. For three years, Dr. Mita led the Phase I Unit as the director of the Institute for Drug Development before being recruited at Cedars Sinai-SOCCI to build the Experiment Therapeutics program. Dr. Mita has been involved as principal investigator or co-investigator in more than 50 phase I studies, and has collaborated with a significant number of companies and pre-clinical colleagues. Her interests are mainly in targeted therapies and personalized medicine, with a focus in breast cancer, sarcoma. At Cedars Sinai Experimental Therapeutics Program, she has open more than 40 studies, and has enrolled over 500 patients in the last six years. Dr. Mita is member of the American Society of Clinical Oncology, the American Association for Cancer Research, the European Society for Medical Oncology, the French Medical Board in Internal Medicine, and the editorial board of Targeted Oncology. She has authored more than 90 articles, more than 120 abstracts, and recently a book on mTOR inhibitors.
Saturday, November 17
10:00 AM – 11:15 AM